Explore this article's sources with AI
Follow PeptideMethods on Google
Tirzepatide Before an Endocrine Crisis
A case linked first-dose tirzepatide timing with a probable pheochromocytoma crisis, but tumor confirmation and drug causality remained unresolved.
Why we wrote this. The report's timing can be mistaken for proof, while the tumor diagnosis and any causal role for tirzepatide both remained unresolved.
In this article (6 sections)
A 2026 case report describes a 48-year-old woman who developed severe abdominal symptoms, fever, lactic acidosis, and a blood pressure of 223/138 mm Hg after her first self-administered dose of tirzepatide. The dose was taken about six hours before symptoms began[1]. Her evaluation supported probable pheochromocytoma, a catecholamine-secreting tumor, but the diagnosis had not been confirmed by functional imaging or pathology. The timing makes a drug-tumor interaction possible. It does not show that tirzepatide caused the crisis.
The report appeared in Medicine on November 13, 2026. The authors called the association hypothesis-generating and scored the adverse drug relationship in the "possible" range. They also identified the tumor's own secretory behavior and acute physiological stress as alternative explanations[1]. Those qualifications are central to reading the case accurately.
The presentation looked like infection
The patient had type 2 diabetes, kidney stones, and spinal stenosis. She arrived with nausea, vomiting, chills, and severe left lower abdominal pain. Her temperature was 39.5°C, heart rate 136 beats per minute, and respiratory rate 24. Laboratory testing found a white blood cell count of 18,000/µL, C-reactive protein of 85 mg/L, procalcitonin of 2.8 ng/mL, and lactate of 8.4 mmol/L[1]. That combination reasonably raised concern for sepsis.
Clinicians started broad-spectrum antibiotics while cultures were pending. The picture then diverged from septic shock. Blood pressure was markedly high rather than low, no vasopressor was needed, blood and urine cultures were negative, and hyperlactatemia appeared out of proportion to perfusion. Antibiotics were stopped as infection became unlikely[1].
Pheochromocytoma can release catecholamines that accelerate glycolysis and raise lactate even when tissue oxygen delivery is adequate. This is described as type B lactic acidosis. Fever, a high white cell count, and inflammatory markers can occur alongside the catecholamine surge, creating a sepsis-like pattern without an identified infection.
Why pheochromocytoma was suspected
The patient reported episodic palpitations over preceding months that had been attributed to anxiety. A 24-hour urine test during the admission found normetanephrines of 1,984 µg, above the laboratory reference of less than 900 µg. Metanephrines were 174 µg, within the reported reference of less than 400 µg, while vanillylmandelic acid was 9.0 mg, above a reference of less than 7.0 mg[1]. The authors said this clinical and biochemical picture supported probable pheochromocytoma.
The Endocrine Society guideline recommends plasma-free or urinary fractionated metanephrines for initial biochemical testing and says positive results require follow-up[2]. Acute physiological stress can reduce test specificity. In this case, testing occurred during a severe acute illness, so the biochemical result supported further evaluation rather than closing the diagnosis.
Computed tomography found a 2.4 cm left adrenal mass containing macroscopic fat with no appreciable contrast enhancement. That appearance favored a myelolipoma, usually a benign adrenal lesion, rather than a typical pheochromocytoma[1]. The authors outlined two unresolved possibilities. The lesion could be an unusual fat-containing pheochromocytoma, or it could be an incidental myelolipoma while catecholamine excess came from another source.
Treatment improved the crisis
The clinical team used intravenous fluids, a nicardipine infusion, electrolyte correction, and oral alpha-blockade with doxazosin. Beta-blockade was withheld until adequate alpha-blockade had been established. Over 48 hours, lactate fell from 8.4 to 2.1 mmol/L as blood pressure and the patient's condition improved[1]. She was discharged on alpha-blockade with plans for 64Cu-DOTATATE functional imaging and surgical evaluation.
That response is compatible with a catecholamine-driven crisis, but it does not identify the trigger. Several treatments were given during the same period, and there was no rechallenge with tirzepatide. The tumor, acute illness, fluid therapy, blood-pressure control, and time all changed together. A single clinical course cannot isolate one cause.
The tirzepatide link remains uncertain
Tirzepatide is a dual GIP and GLP-1 receptor agonist. The Mounjaro prescribing information identifies it as a medicine used with diet and exercise to improve glycemic control in adults and pediatric patients with type 2 diabetes[3]. The case report does not establish a recognized adverse-effect pattern involving pheochromocytoma crisis.
The authors noted biological reasons to investigate a possible interaction, including published observations of GLP-1 receptor expression in pheochromocytoma tissue. Their own drug assessment stayed cautious. Tirzepatide was discontinued and not given again, the tumor provided a strong alternative cause, and the diagnosis itself remained presumptive[1]. A temporal sequence can generate a research question without answering it.
There is also no denominator. This report does not say how many people with known or unrecognized pheochromocytoma have used tirzepatide without a crisis. It cannot estimate incidence, compare risk with other diabetes medicines, or show that first-dose exposure is uniquely relevant. The case is evidence that an event occurred after exposure, not evidence of a population-level drug risk.
What the case cannot settle
The adrenal mass had not been characterized by the planned functional scan, removed, or examined by a pathologist when the report was written. The acute setting may have affected biochemical testing. The paper therefore cannot confirm where the catecholamines came from, whether the fat-containing mass was the source, or whether tirzepatide changed tumor secretion.
A stronger assessment would require confirmed tumor diagnosis, careful timing of exposure and biomarkers, exclusion of other triggers, and observations across more than one patient. Mechanistic work would also need to test whether GLP-1 or GIP receptor activation changes catecholamine release in relevant human tumor tissue. Until then, the tirzepatide research overview should keep this report separate from controlled safety evidence.
How to read the report
The strongest lesson is diagnostic. Severe hypertension plus unexplained lactic acidosis can point toward catecholamine excess even when fever and inflammatory markers initially suggest infection. The case also shows why an adrenal mass that looks fatty on one scan does not end the evaluation when biochemical and clinical findings point elsewhere.
Whether tirzepatide contributed remains open. This single report supports attention and further study, not a claim that the medicine caused pheochromocytoma or routinely triggers crisis. Readers should not stop or change prescribed tirzepatide because of this case. Severe abdominal pain, persistent vomiting, palpitations, or signs of a hypertensive emergency require urgent medical assessment based on the person's actual symptoms and history.
Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.
Frequently asked
Did tirzepatide cause the pheochromocytoma crisis?
The case report cannot establish that. Symptoms began after a first dose, but the probable tumor and acute stress were alternative causes. The authors rated the drug relationship as possible and hypothesis-generating.
Was pheochromocytoma confirmed in this patient?
No. Clinical findings and urinary normetanephrines supported a probable diagnosis, but functional imaging and pathology were still pending. The adrenal mass also had an atypical fat-containing appearance.
Why did the presentation resemble sepsis?
The patient had fever, tachycardia, leukocytosis, inflammatory markers, abdominal symptoms, and severe lactic acidosis. Catecholamine excess can raise lactate and produce systemic features even without infection.
What can one case report tell us about tirzepatide risk?
It can identify a possible signal and define questions for further study. It cannot estimate frequency, prove causation, or show that people using tirzepatide generally face this event.
Sources
- [1]Khan AA et al. When hypertensive crisis mimics septic shock: a case report of pheochromocytoma-induced severe lactic acidosis following GLP-1 receptor agonist administration. Medicine. 2026.Tier 1 · primary↩
- [2]Lenders JWM et al. Pheochromocytoma and paraganglioma: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014. PMID 24893135.Tier 1 · primary↩
- [3]Mounjaro (tirzepatide) prescribing information. DailyMed.Tier 1 · primary↩
No revisions yet. First published .